Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

PPARγ as a Potential Target to Treat Airway Mucus Hypersecretion in Chronic Airway Inflammatory Diseases.

Shen Y, Chen L, Wang T, Wen F.

PPAR Res. 2012;2012:256874. doi: 10.1155/2012/256874. Epub 2012 Jun 17.

2.

Treatment of airway mucus hypersecretion.

Rogers DF, Barnes PJ.

Ann Med. 2006;38(2):116-25. Review.

PMID:
16581697
3.
4.

Bronchial epithelium as a target for innovative treatments in asthma.

Gras D, Chanez P, Vachier I, Petit A, Bourdin A.

Pharmacol Ther. 2013 Dec;140(3):290-305. doi: 10.1016/j.pharmthera.2013.07.008. Epub 2013 Jul 21. Review.

PMID:
23880290
5.

Peroxisome proliferator activated receptor-gamma modulates reactive oxygen species generation and activation of nuclear factor-kappaB and hypoxia-inducible factor 1alpha in allergic airway disease of mice.

Lee KS, Kim SR, Park SJ, Park HS, Min KH, Jin SM, Lee MK, Kim UH, Lee YC.

J Allergy Clin Immunol. 2006 Jul;118(1):120-7. Epub 2006 May 19.

PMID:
16815147
6.

Peroxisome proliferator-activated receptor gamma as a novel therapeutic target in asthma.

Park SJ, Lee YC.

J Asthma. 2008 Jan-Feb;45(1):1-8. doi: 10.1080/02770900701247319. Review.

PMID:
18259989
7.

Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation.

Belvisi MG, Hele DJ, Birrell MA.

Eur J Pharmacol. 2006 Mar 8;533(1-3):101-9. Epub 2006 Feb 3. Review.

PMID:
16458290
8.

Peroxisome proliferator-activated receptor gamma agonist down-regulates IL-17 expression in a murine model of allergic airway inflammation.

Park SJ, Lee KS, Kim SR, Min KH, Choe YH, Moon H, Chae HJ, Yoo WH, Lee YC.

J Immunol. 2009 Sep 1;183(5):3259-67. doi: 10.4049/jimmunol.0900231. Epub 2009 Jul 29.

9.

New pharmacotherapy for airway mucus hypersecretion in asthma and COPD: targeting intracellular signaling pathways.

Lai H, Rogers DF.

J Aerosol Med Pulm Drug Deliv. 2010 Aug;23(4):219-31. doi: 10.1089/jamp.2009.0802. Review.

PMID:
20695774
10.

Genes associated with MUC5AC expression in small airway epithelium of human smokers and non-smokers.

Wang G, Xu Z, Wang R, Al-Hijji M, Salit J, Strulovici-Barel Y, Tilley AE, Mezey JG, Crystal RG.

BMC Med Genomics. 2012 Jun 7;5:21. doi: 10.1186/1755-8794-5-21.

11.

Ineffective correction of PPARγ signaling in cystic fibrosis airway epithelial cells undergoing repair.

Bou Saab J, Bacchetta M, Chanson M.

Int J Biochem Cell Biol. 2016 Sep;78:361-369. doi: 10.1016/j.biocel.2016.07.035. Epub 2016 Jul 30.

PMID:
27484450
12.

Down-regulated peroxisome proliferator-activated receptor γ (PPARγ) in lung epithelial cells promotes a PPARγ agonist-reversible proinflammatory phenotype in chronic obstructive pulmonary disease (COPD).

Lakshmi SP, Reddy AT, Zhang Y, Sciurba FC, Mallampalli RK, Duncan SR, Reddy RC.

J Biol Chem. 2014 Mar 7;289(10):6383-93. doi: 10.1074/jbc.M113.536805. Epub 2013 Dec 24.

13.

Peroxisome proliferator-activated receptor-gamma in cystic fibrosis lung epithelium.

Perez A, van Heeckeren AM, Nichols D, Gupta S, Eastman JF, Davis PB.

Am J Physiol Lung Cell Mol Physiol. 2008 Aug;295(2):L303-13. doi: 10.1152/ajplung.90276.2008. Epub 2008 Jun 13.

14.

Peroxisome proliferator-activated receptor gamma regulates eosinophil functions: a new therapeutic target for allergic airway inflammation.

Ueki S, Matsuwaki Y, Kayaba H, Oyamada H, Kanda A, Usami A, Saito N, Chihara J.

Int Arch Allergy Immunol. 2004 Jun;134 Suppl 1:30-6. Review.

PMID:
15166481
15.

PPARγ Ligands Regulate Noncontractile and Contractile Functions of Airway Smooth Muscle: Implications for Asthma Therapy.

Donovan C, Tan X, Bourke JE.

PPAR Res. 2012;2012:809164. doi: 10.1155/2012/809164. Epub 2012 Aug 16.

17.

Mucous hypersecretion and relationship to cough.

Nadel JA.

Pulm Pharmacol Ther. 2013 Oct;26(5):510-3. doi: 10.1016/j.pupt.2013.02.003. Epub 2013 Feb 19.

PMID:
23434445
18.

Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease.

Belvisi MG, Mitchell JA.

Br J Pharmacol. 2009 Oct;158(4):994-1003. doi: 10.1111/j.1476-5381.2009.00373.x. Epub 2009 Aug 24. Review.

19.

Airway mucus hypersecretion in asthma: an undervalued pathology?

Rogers DF.

Curr Opin Pharmacol. 2004 Jun;4(3):241-50. Review.

PMID:
15140415
20.

Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates acrolein-induced airway mucus hypersecretion in rats.

Liu DS, Liu WJ, Chen L, Ou XM, Wang T, Feng YL, Zhang SF, Xu D, Chen YJ, Wen FQ.

Toxicology. 2009 Jun 16;260(1-3):112-9. doi: 10.1016/j.tox.2009.03.016. Epub 2009 Apr 5.

PMID:
19464576

Supplemental Content

Support Center